Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line [Yahoo! Finance]
Johnson & Johnson (JNJ) had its price target raised by JPMorgan Chase & Co. from $225.00 to $250.00. They now have a "neutral" rating on the stock.
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
The Top High Yield ETFs Every Retiree Should Own [Yahoo! Finance]
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]